Vlado Perkovic
0000-0002-4257-7620
Publication & Citation Trends
Publications
0 total
WCN26-7232 EFFECTS OF CANAGLIFLOZIN ON BETA-CELL FUNCTION AND INSULIN RESISTANCE IN TYPE 2 DIABETES MELLITUS: DATA FROM THE CANVAS TRIAL
Cited by 0
Semantic Scholar
A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy.
Cited by 1
Semantic Scholar
Iptacopan in IgA Nephropathy — Final 24-Month Data
Cited by 0
Semantic Scholar
WCN26-5467 ASPIrin to Reduce Events in Dialysis (ASPIRED) trial: a pragmatic, registry-based, double-blind randomized clinical trial
Cited by 0
Semantic Scholar
WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
Cited by 0
Semantic Scholar
WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE
Cited by 8
Semantic Scholar
WCN25-1900 Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial
Cited by 0
Semantic Scholar
WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
Cited by 0
Semantic Scholar
Research Topics
Diabetes Treatment and Management
(298)
Chronic Kidney Disease and Diabetes
(140)
Dialysis and Renal Disease Management
(120)
Blood Pressure and Hypertension Studies
(112)
Pancreatic function and diabetes
(99)
Affiliations
AstraZeneca (United Kingdom)
Oslo University Hospital
Office of Education
Novartis (Switzerland)
University of Sydney